>So simple....so to the point.....GTCB should operate in this area where they have an unfair advantage.<
Agree. Let companies like MRK and Roche (MAXY’s partner) experiment with tweaking their compounds—that’s their only chance to add value. GTC does not need to take those kinds of risks and probably won’t.
Market Data 
Markets 
AI
